Lilly CEO says patent decisions threaten Canadian R&D jobs

Eli Lilly ($LLY) CEO John Lechleiter isn't in the least bit satisfied with the legal reasoning behind Canadian court decisions stripping patent protection from some of the company's biggest products. And he's suggesting that the country might like to reconsider if it wants to hang on to its R&D industry and the 500 staffers that Lilly still has left in Canada. "If that sort of pattern persists, it's not a question of would we stay in Canada, it's a question of would we have any business in Canada," Lechleiter told the Globe and Mail's editorial board. Patent losses have already cost the company 280 jobs in Canada, says the CEO. Story


Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.